BRIEF-Biogen says Opicinumab missed primary endpoint in study
June 07, 2016 at 07:43 AM EDT
* Says Reports Top Line results from phase 2 study of Opicinumab (anti-lingo-1) in multiple sclerosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.